Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR-Reduced.

Humans Heart Failure Sodium-Glucose Transporter 2 Inhibitors / therapeutic use Stroke Volume Body Mass Index Weight Loss
Body mass index Empagliflozin Heart failure Weight loss

Journal

European journal of heart failure
ISSN: 1879-0844
Titre abrégé: Eur J Heart Fail
Pays: England
ID NLM: 100887595

Informations de publication

Date de publication:
01 2023
Historique:
revised: 20 10 2022
received: 09 08 2022
accepted: 22 10 2022
pubmed: 4 11 2022
medline: 1 2 2023
entrez: 3 11 2022
Statut: ppublish

Résumé

Baseline body mass index (BMI) and weight loss promoted by sodium-glucose cotransporter 2 inhibitors may impact outcomes in patients with heart failure with reduced ejection fraction (HFrEF). We assessed in the EMPEROR-Reduced population treated with empagliflozin versus placebo the relationship between baseline BMI, weight loss and effects on the primary (time to first hospitalization for heart failure [HHF] or cardiovascular death) and key secondary outcomes. We categorized patients according to their baseline BMI: <20 kg/m The benefits of empagliflozin versus placebo were consistently present across all BMI categories in HFrEF patients. Weight loss was associated with higher risk of all-cause mortality, regardless of treatment group.

Identifiants

DOI: 10.1002/ejhf.2728 PMID: 36325584 PMC: PMC10098519
pubmed: 36325584
doi: 10.1002/ejhf.2728
pmc: PMC10098519
doi:

Substances chimiques

empagliflozin HDC1R2M35U
Sodium-Glucose Transporter 2 Inhibitors 0

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

117-127

Commentaires et corrections

Type : CommentIn
Type : ErratumIn

Informations de copyright

© 2022 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

Références

Eur J Heart Fail. 2018 Sep;20(9):1269-1277
pubmed: 29963737
Card Fail Rev. 2017 Apr;3(1):7-11
pubmed: 28785469
Obesity (Silver Spring). 2018 Jan;26(1):70-80
pubmed: 29165885
Eur Heart J. 2015 Oct 21;36(40):2729-32
pubmed: 26341892
Int J Cardiol. 2012 Dec 15;162(1):20-6
pubmed: 22037349
Circulation. 2020 Apr 21;141(16):e750-e772
pubmed: 32148086
Lancet. 2003 Mar 29;361(9363):1077-83
pubmed: 12672310
Eur Heart J Cardiovasc Pharmacother. 2021 Jan 16;7(1):59-67
pubmed: 32096865
World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253
pubmed: 11234459
Circulation. 2016 Dec 6;134(23):e535-e578
pubmed: 27799274
Wien Klin Wochenschr. 2016 Dec;128(Suppl 7):446-454
pubmed: 27885423
Eur J Heart Fail. 2021 Oct;23(10):1662-1672
pubmed: 34272791
Circulation. 2018 Mar 27;137(13):1391-1406
pubmed: 29581366
Nat Clin Pract Cardiovasc Med. 2007 Aug;4(8):436-43
pubmed: 17653116
N Engl J Med. 2020 Oct 8;383(15):1413-1424
pubmed: 32865377
Mayo Clin Proc. 2017 Feb;92(2):266-279
pubmed: 28109619
Circulation. 2021 May 25;143(21):e984-e1010
pubmed: 33882682
Eur Heart J Suppl. 2019 Dec;21(Suppl L):L24-L27
pubmed: 31885509
Am Heart J. 2007 Jan;153(1):74-81
pubmed: 17174642
Eur J Heart Fail. 2021 Oct;23(10):1673-1676
pubmed: 34427026
Diabetes Care. 2013 Dec;36(12):4015-21
pubmed: 24186878
Lancet. 1997 Apr 12;349(9058):1050-3
pubmed: 9107242
Nat Commun. 2020 Jan 9;11(1):163
pubmed: 31919418
N Engl J Med. 2002 Aug 1;347(5):305-13
pubmed: 12151467
Eur J Heart Fail. 2019 Oct;21(10):1270-1278
pubmed: 31584231

Auteurs

Stefan D Anker (SD)

Department of Cardiology and Berlin Institute of Health Center for Regenerative Therapies, and German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin Berlin, Berlin, Germany.
Institute of Heart Diseases, Wrocław Medical University, Wrocław, Poland.

Muhammad Shahzeb Khan (MS)

Division of Cardiology, Duke University School of Medicine, Durham, NC, USA.

Javed Butler (J)

Baylor Scott and White Research Institute, Dallas, TX, USA.
Department of Medicine, University of Mississippi School of Medicine, Jackson, MS, USA.

Anne Pernille Ofstad (AP)

Medical Department, Boehringer Ingelheim Norway KS, Asker, Norway.
Oslo Diabetes Research Center, Oslo, Norway.

Barbara Peil (B)

Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.

Egon Pfarr (E)

Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.

Wolfram Doehner (W)

Department of Cardiology and Berlin Institute of Health Center for Regenerative Therapies, and German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin Berlin, Berlin, Germany.

Naveed Sattar (N)

School of Cardiovascular and Metabolic Health University of Glasgow, BHF Glasgow Cardiovascular Research Centre (GCRC), Glasgow, UK.

Andrew J S Coats (AJS)

University of Warwick, Coventry, UK.

Gerasimos Filippatos (G)

National and Kapodistrian University of Athens School of Medicine, Athens University Hospital Attikon, Athens, Greece.

João Pedro Ferreira (JP)

Centre d'Investigation Clinique-Plurithématique INSERM CIC-P 1433, and INSERM U1116 CHRU Nancy Brabois F-CRIN INI-CRCT, Université de Lorraine, Nancy, France.
UnIC@RISE, Cardiovascular R&D Center, Faculty of Medicine, University of Porto, Porto, Portugal.

Faiez Zannad (F)

Centre d'Investigation Clinique-Plurithématique INSERM CIC-P 1433, and INSERM U1116 CHRU Nancy Brabois F-CRIN INI-CRCT, Université de Lorraine, Nancy, France.

Stuart Pocock (S)

London School of Hygiene and Tropical Medicine, London, UK.

Milton Packer (M)

Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX, USA.
Imperial College, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Weight change and clinical outcomes in heart...
questionsmedicales.fr › Maladies cardiovasculaires › Cardiopathies › Défaillance cardiaque › Weight change and clinical outcomes in heart...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Hypoglycémiants › Inhibiteurs du cotransporteur sodium-glucose de type 2 › Weight change and clinical outcomes in heart...
questionsmedicales.fr › Phénomènes physiologiques respiratoires et circulatoires › Phénomènes physiologiques cardiovasculaires › Hémodynamique › Débit cardiaque › Débit systolique › Weight change and clinical outcomes in heart...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Mesures épidémiologiques › Biométrie › Anthropométrie › Indice de masse corporelle › Weight change and clinical outcomes in heart...
questionsmedicales.fr › Phénomènes physiologiques › Croissance et développement › Croissance › Mensurations corporelles › Poids › Modifications du poids corporel › Perte de poids › Weight change and clinical outcomes in heart...